[Form 4] ANI Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Antonio R. Pera, a director of ANI Pharmaceuticals, Inc. (ANIP), reported the sale of 5,421 shares of the issuer's common stock on 08/20/2025 at a weighted average sales price of $89.73 per share, reducing his direct holdings to 29,952 shares. The Form 4 notes the shares were sold in multiple trades at prices ranging from $89.27 to $90.18. The filing was signed on behalf of Mr. Pera by an attorney-in-fact.

Insights

Securities Analyst

TL;DR: Director sold a modest block of shares at ~$89.73, leaving a meaningful residual stake of 29,952 shares.

The transaction is a straightforward, reported insider sale by director Antonio R. Pera. The sale of 5,421 shares was executed in multiple trades at prices between $89.27 and $90.18, with the Form 4 showing a weighted average price of $89.73. Following the sale, Mr. Pera retains 29,952 shares directly. This disclosure meets Section 16 reporting requirements and contains no additional derivative activity or amendments. From a market-impact perspective, the sale size appears routine relative to typical director filings and is adequately disclosed.

Corporate Governance Expert

TL;DR: Properly filed insider sale; documentation and price range are clearly disclosed.

The Form 4 identifies the reporting person, relationship to the issuer (Director), transaction date, and the post-transaction beneficial ownership. The explanatory remark clarifies the range of trade prices and the method used to report a weighted average price. The form is signed by an attorney-in-fact, which is permissible when properly authorized. There are no indications of option exercises, open-market purchases, or suspicious concentration changes in ownership within this filing.

Insider Trade Summary

Net Seller: 5,421 shares ($486,426)

Net Sell 1 txn

Insider Pera Antonio R

Role Director

Sold 5,421 shs ($486K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,421	$89.73	$486K

Holdings After Transaction: Common Stock — 29,952 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pera Antonio R

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2025		S		5,421	D	$89.73(1)	29,952	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold in multiple trades at prices ranging from $89.27 to $90.18. The price reported above reflects the weighted average sales price.

Remarks:

	/s/ Antonio R. Pera, by attorney-in-fact Meredith W. Cook	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.